Propellon Therapeutics Inc. (Triphase Accelerator)

oicr.on.ca
Innovation Type:
Therapeutics
Cancer Type:
Heme
Funding Stage:
Exit
Fund:
Development of WDR5 Inhibitors for Leukemia and Solid Tumours

Related news

    CONNECT WITH FACIT

    Learn more about how we are driving made-in-Ontario oncology innovations reach the market.